U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07286214) titled 'Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica' on Dec. 10.
Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-group, Phase 4, 3-group study to assess whether treatment with sarilumab at either 150 mg q2w (once every two weeks) or at 200 mg q2w, each given with a 52-week prednisone taper, is superior to placebo given with a 52-week prednisone taper in participants with early polymyalgia rheumatica (PMR) and to determine the safety and tolerability of the sarilumab regimens.
The study will consist of the following visits:
Visit 1 (D-42 to D-1): Screening, Visit 2 (D1): Baselin...